Paracetamol dosing in hospital and on discharge for older people who are frail or have low body weight.


Journal

British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323

Informations de publication

Date de publication:
10 2022
Historique:
revised: 26 04 2022
received: 07 02 2022
accepted: 29 04 2022
pubmed: 11 5 2022
medline: 14 9 2022
entrez: 10 5 2022
Statut: ppublish

Résumé

To describe paracetamol dosing and liver function test (LFT) monitoring in older hospital inpatients who are frail or have low body weight. Retrospective observational study, at a 790-bed metropolitan public health service in Australia. Patients aged ≥70 years, with body weight <50 kg or frailty index based on laboratory data (FI-Lab) score ≥0.3, who were administered paracetamol during an admission with length-of-stay >72 hours, were included. Data were extracted from electronic medical records. Paracetamol doses administered in hospital, and doses prescribed on discharge, were compared against consensus guidelines that recommended ≤60 mg/kg/d for older people weighing <50 kg, and ≤3000 mg/d for frail older people. In total, 240 admissions (n = 229 patients, mean age 84.7 years) were analysed. During 150 (62.5%) admissions, higher than recommended paracetamol doses were prescribed. On 138 (57.5%) occasions, patients were prescribed paracetamol on discharge, and 112/138 (81.2%) doses were higher than recommended. Most discharge prescriptions (97/138, 70.3%) were for regular administration. The median daily dose on discharge for patients <50 kg was 83.7 mg/kg (interquartile range 73.6-90.9 mg/kg). For frail patients ≥50 kg, the median daily discharge dose was 3990 mg (interquartile range 3000-4000 mg). LFTs were measured in hospital for 151/200 (75.5%) and 93/166 (56.0%) patients who received paracetamol for >48 hours and >5 days, respectively. Majority of paracetamol doses prescribed for frail or low-weight older patients in hospital and on discharge were higher than recommended in consensus guidelines. LFTs were not measured for 44% patients who received paracetamol regularly for >5 days. Further studies are needed to explore long-term outcomes of this practice.

Identifiants

pubmed: 35535712
doi: 10.1111/bcp.15394
pmc: PMC9546042
doi:

Substances chimiques

Acetaminophen 362O9ITL9D

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

4565-4572

Informations de copyright

© 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Références

Med J Aust. 2015 Apr 20;202(7):373-7
pubmed: 25877120
CMAJ. 2020 Jan 6;192(1):E3-E8
pubmed: 31907228
Int J Clin Pharm. 2021 Jun;43(3):681-688
pubmed: 33124678
J Clin Transl Hepatol. 2016 Jun 28;4(2):131-42
pubmed: 27350943
BMJ. 2011 Jul 15;343:d4065
pubmed: 21765198
Clin Interv Aging. 2017 Jun 28;12:1029-1040
pubmed: 28721031
Drug Ther Bull. 2018 Jun;56(6):69-72
pubmed: 29903753
J Gerontol A Biol Sci Med Sci. 2007 Jul;62(7):738-43
pubmed: 17634321
Gut. 2005 May;54(5):686-90
pubmed: 15831917
Drugs Aging. 2018 Jul;35(7):603-624
pubmed: 29916138
J Clin Pharm Ther. 2016 Oct;41(5):515-8
pubmed: 27426404
Br J Clin Pharmacol. 2022 Oct;88(10):4565-4572
pubmed: 35535712
Age Ageing. 2016 Jul;45(4):566-7
pubmed: 27103600
Med J Aust. 2021 Sep 20;215(6):261-268
pubmed: 34272737
BMC Med. 2014 Oct 07;12:171
pubmed: 25288274
Med J Aust. 2021 Apr;214(7):324-331
pubmed: 33786837
Eur J Clin Pharmacol. 2019 Aug;75(8):1143-1151
pubmed: 30972451
Geroscience. 2017 Aug;39(4):447-455
pubmed: 28866737
BMC Med. 2015 Jul 13;13:161
pubmed: 26166298
Age Ageing. 2007 Sep;36(5):582-4
pubmed: 17715157
J Am Geriatr Soc. 2005 Nov;53(11):1921-9
pubmed: 16274373
Clin Interv Aging. 2019 Feb 25;14:473-484
pubmed: 30880928
J Clin Pharm Ther. 2011 Jun;36(3):327-35
pubmed: 21545612
Br J Clin Pharmacol. 2011 Mar;71(3):351-64
pubmed: 21284694
J Am Med Inform Assoc. 2006 Mar-Apr;13(2):138-47
pubmed: 16357358
Cochrane Database Syst Rev. 2020 May 8;5:CD012419
pubmed: 32383493
BMC Med Inform Decis Mak. 2017 Apr 10;17(1):36
pubmed: 28395667
Br J Clin Pharmacol. 2004 Jan;57(1):6-14
pubmed: 14678335
Eur J Clin Pharmacol. 2018 Feb;74(2):147-160
pubmed: 29067481
Aging Clin Exp Res. 2018 Dec;30(12):1445-1452
pubmed: 30259498

Auteurs

Olivia Reid (O)

Pharmacy Department, Austin Health, Victoria, Australia.

Janet Ngo (J)

Pharmacy Department, Austin Health, Victoria, Australia.

Samanta Lalic (S)

Pharmacy Department, Austin Health, Victoria, Australia.
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Victoria, Australia.
Pharmacy Department, Monash Health, Victoria, Australia.

Elizabeth Su (E)

Pharmacy Department, Austin Health, Victoria, Australia.

Rohan A Elliott (RA)

Pharmacy Department, Austin Health, Victoria, Australia.
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Victoria, Australia.
Victorian Poisons Information Centre, Austin Health, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH